Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 2 1

Status

Not yet recruiting 7Completed 6Unknown 5Recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Genitourinary 3Tumor-Agnostic 2Other solid neoplasm 2Breast 2Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 6Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × fluzoparib × Gynecologic × Clear all
NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
252 enrolled
Gynecologic

Ovarian Neoplasms

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
100 enrolled
Gynecologic

Ovarian Neoplasms

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03509636 2022-07-01

A Study of Fluzoparib(SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
113 enrolled
Gynecologic

Ovarian Neoplasms

NCT02575651 2019-06-17

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
79 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡